Contribution of major metabolites toward complex drug-drug interactions of deleobuvir: In vitro predictions and in vivo outcomes

Drug Metabolism and Disposition

Volumn 44, Issue 3, 2016, Pages 466-475

  Sane, Rucha S ^a   Ramsden, Diane ^a   Sabo, John P ^a   Cooper, Curtis ^b   Rowland, Lois ^a   Ting, Naitee ^a   Whitcher Johnstone, Andrea ^a   Tweedie, Donald J ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CD 6168; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DELEOBUVIR; DELEOBUVIR ACYL GLUCURONIDE; DRUG METABOLITE; FALDAPREVIR; MESSENGER RNA; MIDAZOLAM; PEGINTERFERON ALPHA2A; RIBAVIRIN; TOLBUTAMIDE; UNCLASSIFIED DRUG; ACRYLIC ACID DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 3A INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG POTENCY; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LIVER CELL; LIVER MICROSOME; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; DRUG INTERACTION; METABOLISM; PHYSIOLOGY;

ACRYLATES; AREA UNDER CURVE; BENZIMIDAZOLES; CYTOCHROME P-450 CYP3A INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HEPATOCYTES; HUMANS; MALE;

EID: 84958969461     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.066985     Document Type: Article

References (46)

1. Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, and Neuvonen PJ (2009) CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos 37:2359-2366.
2. Brennan BJ, Xu ZX, and Grippo JF (2013) Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. Br J Clin Pharmacol 75:497-506.
3. Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518.
4. Callegari E, Kalgutkar AS, Leung L, Obach RS, Plowchalk DR, and Tse S (2013) Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development. Drug Metab Dispos 41:2047-2055.
5. Chen LZ, Sabo JP, Philip E, Rowland L, Mao Y, Latli B, Ramsden D, Mandarino DA, and Sane RS (2015) Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59:25-37.
6. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M, and Skerjanec A (2009) In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos 37:1339-1354.
7. Einolf HJ, Chen L, Fahmi OA, Gibson CR, Obach RS, Shebley M, Silva J, Sinz MW, Unadkat JD, and Zhang L, et al. (2014) Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther 95:179-188.
8. EMA (2012) European Medicines Agency; Committee for Human Medicinal Products (CHMP); Guideline on the investigation of drug interactions. 6-21-2012. 9-13-0013. Online source Faber MS and Fuhr U (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 76:178-184.
9. Fahmi OA, Boldt S, Kish M, Obach RS, and Tremaine LM (2008a) Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 36:1971-1974.
10. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, and Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drugdrug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
11. Fahmi OA, Kish M, Boldt S, and Obach RS (2010) Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 38:1605-1611.
12. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008b) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
13. FDA (2012) Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing and Labeling Recommendations (Draft). 9-13-0013.
14. Fuhr U, Jetter A, and Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther 81:270-283.
15. Galetin A, Gertz M, and Houston JB (2008) Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4:909-922.
16. Gupta SK, Kolz K, and Cutler DL (2011) Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol 67:591-599.
17. Hinton LK, Galetin A, and Houston JB (2008) Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 25:1063-1074.
18. Lin JH (2006) CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 23:1089-1116.
19. Lutz JD, VandenBrink BM, Babu KN, Nelson WL, Kunze KL, and Isoherranen N (2013) Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems. Drug Metab Dispos 41:2056-2065.
20. McCabe M, Sane RS, Keith-Luzzi M, Xu J, King I, Whitcher-Johnstone A, Johnstone N, Tweedie DJ, and Li Y (2015) Defining the role of gut bacteria in the metabolism of deleobuvir: in vitro and in vivo studies. Drug Metab Dispos 43:1612-1618 10.1124/dmd.115.064477.
21. Medina-Díaz IM, Estrada-Muñiz E, Reyes-Hernández OD, Ramírez P, Vega L, and Elizondo G (2009) Arsenite and its metabolites, MMA(III) and DMA(III), modify CYP3A4, PXR and RXR alpha expression in the small intestine of CYP3A4 transgenic mice. Toxicol Appl Pharmacol 239:162-168.
22. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
23. Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, and Desta Z (2010) Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 38:1218-1229.
24. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
25. Ohno Y, Hisaka A, and Suzuki H (2007) General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46:681-696.
26. Petzer JP, Navamal M, Johnson JK, Kwak MK, Kensler TW, and Fishbein JC (2003) Phase 2 enzyme induction by the major metabolite of oltipraz. Chem Res Toxicol 16:1463-1469.
27. Piedade R, Traub S, Bitter A, Nüssler AK, Gil JP, Schwab M, and Burk O (2015) Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor. Antimicrob Agents Chemother 59:96-104.
28. Renwick AB, Watts PS, Edwards RJ, Barton PT, Guyonnet I, Price RJ, Tredger JM, Pelkonen O, Boobis AR, and Lake BG (2000) Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 28:1202-1209.
29. Rowland Yeo K, Jamei M, Yang J, Tucker GT, and Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39:298-309.
30. Sabo JP, Kort J, Ballow C, Kashuba AD, Haschke M, Battegay M, Girlich B, Ting N, Lang B, and Zhang W, et al. (2015) Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation. J Clin Pharmacol 55: 467-477.
31. Säll C, Houston JB, and Galetin A (2012) A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab Dispos 40:1279-1289.
32. Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L, and Skiles GL (2008) Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 36: 2355-2370.
33. Sinz M, Wallace G, and Sahi J (2008) Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10:391-400.
34. Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyrönen TH, Tapaninen T, Neuvonen PJ, Niemi M, and Backman JT (2014) Glucuronidation converts clopidogrel to a strong timedependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther 96:498-507.
35. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, and Kumar V (2013a) Mechanistic modeling to predict the transporter-and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res 30:1188-1199.
36. Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, El-Kattan AF, Goosen TC, and Lai Y (2013b) Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos 41:966-974.
37. Venkatakrishnan K and Obach RS (2007) Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 8:449-462.
38. Venkatakrishnan K, Obach RS, and Rostami-Hodjegan A (2007) Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 37:1225-1256.
39. Wang JS, Neuvonen M, Wen X, Backman JT, and Neuvonen PJ (2002) Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352-1356.
40. Yu H and Tweedie D (2013) A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency. Drug Metab Dispos 41:536-540.
41. Yu H, Balani SK, Chen W, Cui D, He L, Humphreys WG, Mao J, Lai WG, Lee AJ, and Lim HK, et al. (2015) Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group. Drug Metab Dispos 43:620-630.
42. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse AW, and Pol S, et al. (2013) Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther 18:1015-1019.
43. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Böcher WO, and Mensa FJ. (2013) Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 369(7):630-9.
44. Zhang JG, Ho T, Callendrello AL, Crespi CL, and Stresser DM (2010) A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with b-naphthoflavone, phenobarbital and rifampicin. Drug Metab Lett 4: 185-194.
45. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, and Wu TC, et al. (2011) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89: 259-267.
46. Zhou SF, Chan E, Zhou ZW, Xue CC, Lai X, and Duan W (2009) Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr Drug Metab 10:713-729.